You are here: Industry Insights > TXA127

News List

Constant Therapeutics Announces Start of Phase 2 Trial of Peptide Drug TXA127 for COVID-19 americanpharmaceuticalreview
August 06, 2020
Constant Therapeutics announced its peptide drug TXA127, a pharmaceutical formulation of the natural human peptide angiotensin-(1-7), will be tested in a Phase 2 clinical trial at Columbia University Irving Medical Center in New York, New York.
TXA127 from Constant Therapeutics Tested in COVID-19 Trials americanpharmaceuticalreview
July 20, 2020
Constant Therapeutics announced its peptide drug TXA127 will be tested in a series of Phase 2 clinical trials in hospitalized COVID-19 patients who are not in the Intensive Care Unit (ICU).
TXA127 enters multiple Phase II trials in COVID-19 patients europeanpharmaceuticalreview
July 14, 2020
A pharmaceutical formulation of the human angiotensin peptide, TXA127, will enter Phase II trials in hospitalised COVID-19 patients not in intensive care.
Constant Pharmaceuticals to Initiate Clinical Development of TXA127 americanpharmaceuticalreview
November 29, 2018
Constant Pharmaceuticals plans to begin a development program for its compound, TXA127, for the treatment of the rare pediatric disease, epidermolysis bullosa in collaboration with.....